Genflow Biosciences plc

Equities

GENF

GB00BP2C3V08

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:14 24/06/2024 pm IST			5-day change	1st Jan Change
2.65 ^GBX	-7.02%		-13.11%	+85.96%

12/06	EARNINGS AND TRADING: Distil loss widens; Genflow welcomes grant	AN
30/05	Genflow Biosciences receives 50% of grant for sarcopenia project	AN

Genflow Biosciences reaffirms commitment to new markets

May 16, 2023 at 12:32 pm IST

(via NewsDirect)

Dr. Eric Leire, CEO of Genflow Biosciences PLC, recently announced exciting developments in the company's fight against nonalcoholic steatohepatitis (NASH), a liver disease that affects millions of people worldwide. Significant progress has been made in its pre-clinical program, targeting fat deposition, fibrosis, and liver cancer associated with NASH.

The company has strengthened its Scientific Advisory Board with the addition of Professor Dr Sven Franque, an expert in NASH and regulatory authorities. Furthermore, Genflow has promoted Tamara Joseph as chairperson, reflecting their commitment to diversity and expanding their presence in the US market. They have also applied to trade on the OTC QB market, and Dr. Leire plans to increase their presence in the US. These advancements highlight Genflow's dedication to addressing the unmet need in NASH treatment.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Genflow Biosciences plc

EARNINGS AND TRADING: Distil loss widens; Genflow welcomes grant	12/06	AN
Genflow Biosciences receives 50% of grant for sarcopenia project	30/05	AN
Genflow Biosciences Secures Grant for Sarcopenia Research Program	30/05	MT
Home REIT cuts borrowings, Genflow shares restored	09/05	AN
Genflow Biosciences Resumes London Trading	08/05	MT
EARNINGS AND TRADING: Solid State and MTI Wireless win deals	07/05	AN
Genflow Biosciences plc Reports Earnings Results for the Full Year Ended December 31, 2023	07/05	CI
Genflow Biosciences to Temporarily Halt Trading Amid Delay in FY23 Results Publication	01/05	MT
Northcoders launches bootcamp; Schroder invests	04/04	AN
Genflow Biosciences Raises New Funds for Liver Disease Treatment Trials	04/04	MT
Genflow confirms publication of European patent for SIRT6	21/03	AN
Genflow wins new research grants; Seeen margin rises	01/02	AN
Coro Energy strikes finance deal in Vietnam	19/01	AN
Genflow Biosciences plc Announces Two Non-Dilutive Research Grant Awards	18/01	CI
Genflow Biosciences first half loss narrows on slashed admin expenses	28/23/28	AN
Hansard Global shares rise as profit jumps	28/23/28	AN
Earnings Flash (GENF.L) GENFLOW BIOSCIENCES Reports H1 Loss GBX-0.21	28/23/28	MT
Genflow Biosciences plc Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Capital inks contract; Lansdowne becomes cash shell	20/23/20	AN
Genflow Biosciences Plc Announces Company Update	20/23/20	CI
Genflow Biosciences begins trading on OTCQB Venture Market in US	13/23/13	AN
Genflow Biosciences Starts Trading on OTCQB Venture Market in US	13/23/13	MT
Genflow Biosciences plc Reports Earnings Results for the Full Year Ended December 31, 2022	08/23/08	CI
Genflow names US non-exec as Chair as readies for US listing	11/23/11	AN
Genflow Biosciences plc Announces Appointment and Internal Restructure	11/23/11	CI

Chart Genflow Biosciences plc

Duration

Period

More charts

Company Profile

Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.

Sector

Biotechnology & Medical Research

Calendar

27/06/2024 - Annual Genearl Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENFLOW BIOSCIENCES PLC	+85.96%	1.18Cr
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	12TCr
REGENERON PHARMACEUTICALS, INC.	+21.13%	11TCr
ARGENX SE	+18.05%	2.59TCr
BIONTECH SE	-17.94%	2.09TCr
GENMAB A/S	-16.24%	1.65TCr
BEIGENE, LTD.	-11.76%	1.68TCr
WUXI APPTEC CO., LTD.	-44.45%	1.56TCr
SAREPTA THERAPEUTICS, INC.	+69.92%	1.55TCr
NEUROCRINE BIOSCIENCES, INC.	+1.41%	1.34TCr

Bio Therapeutic Drugs